Tenaya Therapeutics *

Tenaya Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on discovering, designing, developing, and delivering potentially curative gene therapies and precision medicines that address the underlying drivers of heart disease. Its clinical pipeline includes TN-201, an AAV-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), both in early clinical development. Publicly traded on Nasdaq as TNYA and backed by investors including GV, the company operates as a therapeutics developer and publishes no public developer platform or API surface.

Tenaya Therapeutics * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Gene Therapy, and Cardiovascular.

Tenaya Therapeutics *’s developer surface includes engineering blog, support, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
10.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesBiotechnologyGene TherapyCardiovascularPrecision MedicineClinical Stage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 10.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 1.0 / 17
Access Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/tenaya-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Tenaya Therapeutics Domain Security

TLSv1.3

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: tenaya-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/tenaya-therapeutics.png
name: Tenaya Therapeutics *
description: Tenaya Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California,
  focused on discovering, designing, developing, and delivering potentially curative gene therapies and precision medicines
  that address the underlying drivers of heart disease. Its clinical pipeline includes TN-201, an AAV-based gene therapy for
  MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy
  (ARVC), both in early clinical development. Publicly traded on Nasdaq as TNYA and backed by investors including GV, the
  company operates as a therapeutics developer and publishes no public developer platform or API surface.
url: https://raw.githubusercontent.com/api-evangelist/tenaya-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Life Sciences
- Biotechnology
- Gene Therapy
- Cardiovascular
- Precision Medicine
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.tenayatherapeutics.com
- type: Blog
  url: https://investors.tenayatherapeutics.com/news-events/news-releases
- type: Support
  url: https://www.tenayatherapeutics.com/contact-us/
- type: PrivacyPolicy
  url: https://www.tenayatherapeutics.com/privacy-policy/
- type: TermsOfService
  url: https://www.tenayatherapeutics.com/terms-of-use
- type: DomainSecurity
  url: security/tenaya-therapeutics-domain-security.yml
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1